Kudaiberdieva Gulmira, Gorenek Bulent
Adana, Turkey.
J Atr Fibrillation. 2013 Jun 30;6(1):880. doi: 10.4022/jafib.880. eCollection 2013 Jun-Jul.
Atrial fibrillation (AF) is a frequently encountered rhythm disorder, characterized by high recurrence rate, frequent hospitalizations, reduced quality-of-life and increased the risk of mortality, heart failure and stroke. Along with these clinical complications this type of arrhythmia is the major driver of health-related expenditures. Radiofrequency catheter ablation (RFA) of atrial fibrillation has been shown to improve freedom from arrhythmia survival, reduce re-hospitalization rate and provide better quality-of-life as compared with rate control and rhythm control with antiarrhythmic therapy. Efficacy of AF ablation in terms of outcomes and costs has an evolving importance. In this review, we aimed to highlight current knowledge on AF ablation clinical outcomes based on results of randomized clinical trials and community-based studies, and overview how this improvement in clinical end-points affects costs for arrhythmia care and cost-effectiveness of AF ablation.
心房颤动(AF)是一种常见的节律紊乱,其特点是复发率高、频繁住院、生活质量下降以及死亡、心力衰竭和中风风险增加。除了这些临床并发症外,这种类型的心律失常还是健康相关支出的主要驱动因素。与抗心律失常治疗的心率控制和节律控制相比,心房颤动的射频导管消融(RFA)已被证明可提高无心律失常生存率、降低再住院率并提供更好的生活质量。房颤消融在结局和成本方面的疗效具有不断演变的重要性。在本综述中,我们旨在根据随机临床试验和基于社区的研究结果突出当前关于房颤消融临床结局的知识,并概述临床终点的这种改善如何影响心律失常护理成本和房颤消融的成本效益。